A citation-based method for searching scientific literature

Daisuke Shiraishi, Yukio Fujiwara, Yoshihiro Komohara, Hiroshi Mizuta, Motohiro Takeya. Biochem Biophys Res Commun 2012
Times Cited: 93







List of co-cited articles
789 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Inhibition of monocyte adhesion to endothelial cells and attenuation of atherosclerotic lesion by a glucagon-like peptide-1 receptor agonist, exendin-4.
Masayuki Arakawa, Tomoya Mita, Kosuke Azuma, Chie Ebato, Hiromasa Goto, Takashi Nomiyama, Yoshio Fujitani, Takahisa Hirose, Ryuzo Kawamori, Hirotaka Watada. Diabetes 2010
361
29

Glucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetes.
Y-S Lee, M-S Park, J-S Choung, S-S Kim, H-H Oh, C-S Choi, S-Y Ha, Y Kang, Y Kim, H-S Jun. Diabetologia 2012
143
16

Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice.
M Nagashima, T Watanabe, M Terasaki, M Tomoyasu, K Nohtomi, J Kim-Kaneyama, A Miyazaki, T Hirano. Diabetologia 2011
164
15

GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice.
Naim Panjwani, Erin E Mulvihill, Christine Longuet, Bernardo Yusta, Jonathan E Campbell, Theodore J Brown, Catherine Streutker, Dianne Holland, Xiemin Cao, Laurie L Baggio,[...]. Endocrinology 2013
232
13

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
13

GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice.
Mohammad Hossein Noyan-Ashraf, M Abdul Momen, Kiwon Ban, Al-Muktafi Sadi, Yu-Qing Zhou, Ali M Riazi, Laurie L Baggio, R Mark Henkelman, Mansoor Husain, Daniel J Drucker. Diabetes 2009
405
11

Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways.
Kiwon Ban, M Hossein Noyan-Ashraf, Judith Hoefer, Steffen-Sebastian Bolz, Daniel J Drucker, Mansoor Husain. Circulation 2008
752
11

Exploring the full spectrum of macrophage activation.
David M Mosser, Justin P Edwards. Nat Rev Immunol 2008
11

GLP-1 receptor stimulation preserves primary cortical and dopaminergic neurons in cellular and rodent models of stroke and Parkinsonism.
Yazhou Li, TracyAnn Perry, Mark S Kindy, Brandon K Harvey, David Tweedie, Harold W Holloway, Kathleen Powers, Hui Shen, Josephine M Egan, Kumar Sambamurti,[...]. Proc Natl Acad Sci U S A 2009
397
11


A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity.
Mohammad Hossein Noyan-Ashraf, Eric Akihiko Shikatani, Irmgard Schuiki, Ilya Mukovozov, Jun Wu, Ren-Ke Li, Allen Volchuk, Lisa Annette Robinson, Filio Billia, Daniel J Drucker,[...]. Circulation 2013
164
9

Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus.
Andrew E Hogan, Gadintshware Gaoatswe, Lydia Lynch, Michelle A Corrigan, Conor Woods, Jean O'Connell, Donal O'Shea. Diabetologia 2014
98
9

Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model.
Paul Richards, Helen E Parker, Alice E Adriaenssens, Joshua M Hodgson, Simon C Cork, Stefan Trapp, Fiona M Gribble, Frank Reimann. Diabetes 2014
264
9

The chemokine system in diverse forms of macrophage activation and polarization.
Alberto Mantovani, Antonio Sica, Silvano Sozzani, Paola Allavena, Annunciata Vecchi, Massimo Locati. Trends Immunol 2004
8

The biology of incretin hormones.
Daniel J Drucker. Cell Metab 2006
8

A GLP-1 receptor agonist liraglutide inhibits endothelial cell dysfunction and vascular adhesion molecule expression in an ApoE-/- mouse model.
Tracey Gaspari, HongBin Liu, Iresha Welungoda, Yunshan Hu, Robert E Widdop, Lotte B Knudsen, Richard W Simpson, Anthony E Dear. Diab Vasc Dis Res 2011
120
8

Protection and reversal of excitotoxic neuronal damage by glucagon-like peptide-1 and exendin-4.
TracyAnn Perry, Norman J Haughey, Mark P Mattson, Josephine M Egan, Nigel H Greig. J Pharmacol Exp Ther 2002
262
8


Regulation of adipocyte formation by GLP-1/GLP-1R signaling.
Tenagne Delessa Challa, Nigel Beaton, Myrtha Arnold, Gottfried Rudofsky, Wolfgang Langhans, Christian Wolfrum. J Biol Chem 2012
81
9

Macrophage plasticity and polarization: in vivo veritas.
Antonio Sica, Alberto Mantovani. J Clin Invest 2012
8

Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease.
Iciar Aviles-Olmos, John Dickson, Zinovia Kefalopoulou, Atbin Djamshidian, Joshua Kahan, Peter Ell, Peter Whitton, Richard Wyse, Tom Isaacs, Andrew Lees,[...]. J Parkinsons Dis 2014
157
8

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Dilan Athauda, Kate Maclagan, Simon S Skene, Martha Bajwa-Joseph, Dawn Letchford, Kashfia Chowdhury, Steve Hibbert, Natalia Budnik, Luca Zampedri, John Dickson,[...]. Lancet 2017
323
8


A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice.
Junichi Matsubara, Seigo Sugiyama, Koichi Sugamura, Taishi Nakamura, Yukio Fujiwara, Eiichi Akiyama, Hirofumi Kurokawa, Toshimitsu Nozaki, Keisuke Ohba, Masaaki Konishi,[...]. J Am Coll Cardiol 2012
213
7

Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.
Zubair Shah, Thomas Kampfrath, Jeffrey A Deiuliis, Jixin Zhong, Colleen Pineda, Zhekang Ying, Xiaohua Xu, Bo Lu, Susan Moffatt-Bruce, Rekha Durairaj,[...]. Circulation 2011
275
7

The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.
Paula L McClean, Vadivel Parthsarathy, Emilie Faivre, Christian Hölscher. J Neurosci 2011
460
7

Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease.
Alexander Harkavyi, Amjad Abuirmeileh, Rebecca Lever, Ann E Kingsbury, Christopher S Biggs, Peter S Whitton. J Neuroinflammation 2008
187
7

Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson's disease.
Göran Bertilsson, Cesare Patrone, Olof Zachrisson, Annica Andersson, Karin Dannaeus, Jessica Heidrich, Jarkko Kortesmaa, Alex Mercer, Elisabet Nielsen, Harriet Rönnholm,[...]. J Neurosci Res 2008
236
7

Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron.
TracyAnn Perry, Debomoy K Lahiri, Kumar Sambamurti, Demao Chen, Mark P Mattson, Josephine M Egan, Nigel H Greig. J Neurosci Res 2003
271
7

Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice.
Xiaokun Ding, Neeraj K Saxena, Songbai Lin, Nitika Arora Gupta, Frank A Anania. Hepatology 2006
396
7

Exendin-4 decreases liver inflammation and atherosclerosis development simultaneously by reducing macrophage infiltration.
Y Wang, E T Parlevliet, J J Geerling, S J L van der Tuin, H Zhang, V Bieghs, A H M Jawad, R Shiri-Sverdlov, I Bot, S C A de Jager,[...]. Br J Pharmacol 2014
68
10

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.
Anne-Marie Lambeir, Christine Durinx, Simon Scharpé, Ingrid De Meester. Crit Rev Clin Lab Sci 2003
639
7


Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance.
Justin I Odegaard, Roberto R Ricardo-Gonzalez, Matthew H Goforth, Christine R Morel, Vidya Subramanian, Lata Mukundan, Alex Red Eagle, Divya Vats, Frank Brombacher, Anthony W Ferrante,[...]. Nature 2007
7

Exenatide exerts a potent antiinflammatory effect.
Ajay Chaudhuri, Husam Ghanim, Mehul Vora, Chang Ling Sia, Kelly Korzeniewski, Sandeep Dhindsa, Antoine Makdissi, Paresh Dandona. J Clin Endocrinol Metab 2012
148
7

Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
7

Exendin-4, a GLP-1 receptor agonist, directly induces adiponectin expression through protein kinase A pathway and prevents inflammatory adipokine expression.
Le Thi Kim Chung, Toshio Hosaka, Masaki Yoshida, Nagakatsu Harada, Hiroshi Sakaue, Tohru Sakai, Yutaka Nakaya. Biochem Biophys Res Commun 2009
97
7

Cardiovascular effects of DPP-4 inhibition: beyond GLP-1.
Gian Paolo Fadini, Angelo Avogaro. Vascul Pharmacol 2011
162
6

Sitagliptin reduces plaque macrophage content and stabilises arteriosclerotic lesions in Apoe (-/-) mice.
F Vittone, A Liberman, D Vasic, R Ostertag, M Esser, D Walcher, A Ludwig, N Marx, M Burgmaier. Diabetologia 2012
77
7

Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury.
Leo Timmers, José P S Henriques, Dominique P V de Kleijn, J Hans Devries, Hans Kemperman, Paul Steendijk, Cees W J Verlaan, Marjolein Kerver, Jan J Piek, Pieter A Doevendans,[...]. J Am Coll Cardiol 2009
350
6

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.
Thomas Nyström, Mark K Gutniak, Qimin Zhang, Fan Zhang, Jens Juul Holst, Bo Ahrén, Ake Sjöholm. Am J Physiol Endocrinol Metab 2004
499
6

Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
Jacob Lønborg, Niels Vejlstrup, Henning Kelbæk, Hans Erik Bøtker, Won Yong Kim, Anders B Mathiasen, Erik Jørgensen, Steffen Helqvist, Kari Saunamäki, Peter Clemmensen,[...]. Eur Heart J 2012
387
6

Incretin-based therapies for type 2 diabetes mellitus.
Julie A Lovshin, Daniel J Drucker. Nat Rev Endocrinol 2009
490
6

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.
Lazaros A Nikolaidis, Sunil Mankad, George G Sokos, Glen Miske, Ankur Shah, Dariush Elahi, Richard P Shannon. Circulation 2004
654
6

The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
6

The glucagon-like peptide 1 analog liraglutide reduces TNF-α-induced oxidative stress and inflammation in endothelial cells.
Aya Shiraki, Jun-ichi Oyama, Hiroshi Komoda, Machiko Asaka, Aiko Komatsu, Masashi Sakuma, Kazuhisa Kodama, Yoshiko Sakamoto, Norihiko Kotooka, Tetsuaki Hirase,[...]. Atherosclerosis 2012
171
6

Obesity is associated with macrophage accumulation in adipose tissue.
Stuart P Weisberg, Daniel McCann, Manisha Desai, Michael Rosenbaum, Rudolph L Leibel, Anthony W Ferrante. J Clin Invest 2003
6



A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells.
TracyAnn Perry, Debomoy K Lahiri, Demao Chen, Jie Zhou, Karen T Y Shaw, Josephine M Egan, Nigel H Greig. J Pharmacol Exp Ther 2002
231
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.